Bristol Myers Squibb Company $BMY Stock: Whittier Trust Co. Grows Holdings

Whittier Trust Co. grew its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 19.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 61,640 shares of the biopharmaceutical company’s stock after purchasing an additional 10,134 shares during the quarter. Whittier Trust Co.’s holdings in Bristol Myers Squibb were worth $3,644,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of BMY. Primecap Management Co. CA acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at about $1,436,115,000. Legal & General Group Plc bought a new position in Bristol Myers Squibb in the 2nd quarter valued at about $980,862,000. BlackRock Inc. lifted its position in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. State Street Corp lifted its position in Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after acquiring an additional 7,192,724 shares during the last quarter. Finally, Caisse de depot et placement du Quebec acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $243,646,000. 76.41% of the stock is owned by institutional investors.

Key Bristol Myers Squibb News

Here’s some of the latest news about BMY:

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BMY. Weiss Ratings restated a “buy (b-)” rating on shares of Bristol Myers Squibb in a report on Monday, November 16th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. The Goldman Sachs Group upgraded Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 16th. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Finally, Morgan Stanley reduced their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research note on Friday, October 30th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $65.46.

Check Out Our Latest Stock Analysis on Bristol Myers Squibb

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $58.81 on Friday. Bristol Myers Squibb Company has a 52 week low of $45.52 and a 52 week high of $68.64. The firm has a market cap of $120.22 billion, a price-to-earnings ratio of 13.04, a P/E/G ratio of 0.30 and a beta of 0.20. The firm’s 50-day simple moving average is $61.45 and its 200 day simple moving average is $60.44. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. The business had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.63 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.88%.

Insider Buying and Selling

In related news, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The SEC filing for this sale provides additional information. 0.05% of the stock is currently owned by insiders.

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Featured Stories

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.